Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.43 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316210 | 0.95 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2RECQLTSHR | |
| SCHEMBL6317913 | 0.87 | MLLT3 (0.41) | TAS1R3TAS1R1TAS1R2KMT2AMLLT3 | |
| SCHEMBL6323374 | 0.86 | CA1 (0.49) | TAS1R3TAS1R1TAS1R2KMT2AMLLT3 | |
| SCHEMBL6318467 | 0.83 | NPC1 (0.59) | KMT2AMLLT3MLLT1RAB9ANPC1 | |
| SCHEMBL6317385 | 0.83 | NPC1 (0.61) | KMT2AMLLT3MLLT1RAB9ANPC1 | |
| SCHEMBL6323161 | 0.83 | ALDH1A1 (0.52) | TAS1R3TAS1R1TAS1R2MLLT3MLLT1 | |
| SCHEMBL6323933 | 0.83 | RECQL (0.47) | TAS1R3TAS1R1TAS1R2RECQLTSHR | |
| SCHEMBL6321193 | 0.82 | NPC1 (0.62) | KMT2AMLLT3MLLT1RAB9ANPC1 | |
| SCHEMBL6316754 | 0.82 | NPC1 (0.62) | KMT2AMLLT3MLLT1RAB9ANPC1 | |
| SCHEMBL6322801 | 0.81 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | TAS1R3 4289/4885TAS1R1 4258/4885TAS1R2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.